Weekly cis-diamminedichloroplatinum II as induction chemotherapy in recurrent carcinoma of the cervix.

Twenty-four evaluable patients with recurrent carcinoma of the cervix after previous pelvic irradiation were treated with cis-diamminedichloroplatinum II (cis-DDP). Of the 14 patients who received low-dose (1 mg/kg) weekly induction cis-DDP, 10 (71%) responded, 6 (43%) of which were complete responses. Four (40%) of the ten patients who received high-dose (100 mg/m2) monthly cis-DDP responded, two of which were complete responses. Maintenance of these responses by combination chemotherapy which includes cis-DDP remains a significant problem.